Study on the action of breviscapus and saliva for in vitro inhibiting platelet activation

Objective To study the action of breviscapus and saliva in inhibiting platelet activation in vitro and to provide more scientific evidence and theoretical basic for the treatment of blood stasis syndrome.Method Two kinds of anti-platelet drugs and controls,which inhibited the expression of fibrinogen receptor(PAC-1)and P-2selectin(CD62P)on activated platelets surface in vitro,were analyzed by tri-color flowcytometry.Results Both of two kinds of anti-platelet drugs can inhibite the expression of PAC-1 and CD62P on ADPactivating platelet membrane surface.With the increase of the concentration of drug,the ability of inhibiting become enhanced.Saliva could inhibit the expression of FIB-1 and CD62P of the platelets markedly.breviscapus could inhibit the PAC-1 expression markedly,but CD62P indistinctly.Conclusion Saliva is a strong anti-platelet drug as compared with breviscapus.It could not only inhibit PAC-1 expression of activated platelets,which can prevent platelet aggregation,but also decrease the release reaction and procoagulative activities of activated platelets.Saliva will play an important role in treatment of thrombus in the feature. Key words: Platelet activation Flow cytometry breviscapus; Saliva